HOME >> MEDICINE >> NEWS
Data showed improved quality of life and patient satisfaction with SYMBICORT

Wilmington, DE May 22, 2007 New data demonstrated that the combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dihydrate), led to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol) or placebo. The results from these two 12-week randomized, double-blind trials were presented at the American Thoracic Society (ATS) 2007 International Conference held in San Francisco, May 18-23.

"Asthma is a chronic disease that can have a significant effect on patients' day-to-day routine, including participating in activities, such as walking to the store or even playing with their children," said Dr. Kevin R. Murphy, Clinical Professor, University of Nebraska Medical Center. "For the millions of asthma sufferers in the U.S., and especially for those whose condition is not adequately controlled with their current medication, SYMBICORT will provide a new option for patients to help manage and control their asthma, allowing them to get back to their daily activities."

SYMBICORT is a recently approved, combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older. SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma. Studies of patients treated with SYMBICORT demonstrated clinically significant improvement in lung function occurring within 15 minutes of beginning treatment. SYMBICORT has safety data in long-term studies of up to one year, and has a robust cardiac safety profile.

"The studies presented at this year's ATS conference provided valuable data on asthma control and asthma-related quality of life with SYMBICORT," said Chris O'Brien, Senior Director, Medical Science, AstraZeneca. "Asthma sufferers will have a new, rapid-acting combination treatment to help them achieve asthma control."

Administere
'"/>

Contact: Tracy Knudsen
Tracy.Knudsen@astrazeneca.com
302-885-1933
AstraZeneca
22-May-2007


Page: 1 2 3

Related medicine news :

1. New analysis showed UC patients in clinical remission had higher rates of employment
2. ROZEREM (ramelteon) showed significant reduction in time to fall asleep
3. New study showed ramelteon helped adults with chronic insomnia fall asleep, sleep longer
4. LSUHSC awarded designation resulting in improved patient safety and outcomes
5. ACP supports improved access to information on relative strengths and weaknesses
6. Performance-related financial incentives for hospitals not linked with improved quality of care
7. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms
8. Alzheimers weight gain initiative also improved patients intellectual abilities
9. Acute coronary syndrome therapy improvements linked with fewer deaths and improved clinical outcomes
10. New study reports improved treatment and reduced mortality for patients with heart failure
11. Lymph node evaluation linked to improved survival for colon cancer patients

Post Your Comments:
(Date:10/31/2014)... treatment and cost, patients with early stage breast ... (APBI) with proton therapy versus whole breast irradiation ... of Texas MD Anderson Proton Therapy Center. ... on typical patient characteristics, researchers used Medicare reimbursement ... types of partial and whole breast irradiation therapies ...
(Date:10/31/2014)... device to give cancer researchers an unprecedented microscopic look ... through the body, causing more than 90 percent of ... cells travel, the device could uncover new ways to ... university,s Whiting School of Engineering and its Institute for ... system recently in the journal Cancer Research . ...
(Date:10/31/2014)... North Shore Eye Care today announced ... Island and the addition of leading ophthalmologist, William S. ... North Shore Eye Care Medical Director, Jeffrey Martin, MD. ... the Department of Ophthalmology of Winthrop-University Hospital and has ... for more than 30 years. He has been named ...
(Date:10/31/2014)... Melbourne, Fl. (PRWEB) October 31, 2014 ... school for boys and girls in grades 6-12, ... the potential for sports injuries and concussions, becoming ... proactively administer the ImPACT (Immediate Post-Concussion Assessment and ... As a 'Former NFL Player' lawsuit grabs the ...
(Date:10/31/2014)... October 31, 2014 Triple Board Certified ... hair restoration services to transform the appearance of military ... American Academy of Facial Plastic and Reconstruction Surgery (AAFPRS) ... to restore the facial hair Jones lost during an ... The pro-bono hair restoration procedure, valued around $16,000, took ...
Breaking Medicine News(10 mins):Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2
(Date:10/31/2014)... BARCELONA , October 31, 2014 ... infringe two Australian patents of B. Braun Melsungen AG (B. ... Australia safety IV catheters manufactured by Poly Medicure ... Australia proceeding number VID 463 of ... In the detailed judgment, Multigate was found to have ...
(Date:10/31/2014)... October 30, 2014 ... the addition of the  "Process Validation in the ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key ... Risk Based Approach to Process Validation for Pharmaceutical ... FDA Process Validation Guidance ...
(Date:10/31/2014)... 2014 Though therapies are in their nascent ... show an annual increase of 16.2% over the 2010-2020 ... billion, according to Kalorama Information,s report, Stem Cell ... therapeutics that have gained or are expected to gain ... developers tackle ever more complicated conditions, stem cell therapies ...
Breaking Medicine Technology:B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Report: Stem Cell Technologies Market Growing 2
Cached News: